English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

INTRODUCTION. Greater than 90% of MM patients progress to a chemoresistant state (1). New therapies are clearly needed for the treatment of refractory MM that overcome or bypass the adaptive cellular changes associated with refractory disease: P-glycoprotein expression, increased Bcl-xL expression, elevated glutathione (GSH). Arsenic cytotoxicity is independent of Bcl-xL expression (2), making it a promising anti-neoplastic agent for MM. Ascorbic acid (AA) has recently been shown to deplete GSH via autooxidation and subsequent reduction reactions (3). Therefore, we hypothesized that the combination of arsenic and AA is likely to induce apoptosis in refractory MM cells.

Ascorbic Acid Augments Arsenic-Mediated Cell Death in Multiple Myeloma (MM) Cells